PMV Pharmaceuticals, Inc. (PMVP)
| Market Cap | 1.99B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 6.02M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $42.33 |
| Previous Close | $44.46 |
| Change ($) | -2.13 |
| Change (%) | -4.79% |
| Day's Open | 44.23 |
| Day's Range | 41.66 - 45.15 |
| Day's Volume | 56,338 |
| 52-Week Range | 31.86 - 61.51 |
There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they believe they can profit remarkably from their investments after the market has...
CRANBURY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnos...
CRANBURY, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnos...
CRANBURY, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnos...
Andreas Halvorsen (Trades, Portfolio) revealed he established a new position in PMV Pharmaceuticals Inc. (NASDAQ:PMVP) on Sept. 25, according to GuruFocus' Real-Time Picks.
CRANBURY, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapie...
U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week
PMV Pharmaceuticals Inc.'s stock debuted with a bang Friday, as the the stock opened at nearly double the initial public offering price. The first trade was at $35.00 at 12:09 p.m.
PMV Pharmaceuticals Inc.'s PMVP, initial public offering priced at $18 a share, which was at the top of the expected range of $16 to $18 a share. The oncology compa...
CRANBURY, N.J., Sept. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapie...
About PMVP
PMV Pharmaceuticals, a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. Its lead product candidate is PC14586, a small molecule that corrects and restores p53 function. The company also develops product candidates for p53 R273H hotspot mutation and other p53 hotspot mutations. PMV Pharmaceuticals, Inc. was formerly known as PJ Pharmaceuticals, Inc. and changed to in July 2013. The company was founded in 2013 and is headquartered in Cranbury, New Jersey.
| Industry Biotechnology | IPO Date Sep 25, 2020 |
| CEO Dr. David H. Mack | Employees 39 |
| Stock Exchange NASDAQ | Ticker Symbol PMVP |
Analyst Forecasts
According to 4 analysts, the average rating for PMVP stock is "Buy." The 12-month stock price forecast is 61.33, which is an increase of 44.89% from the latest price.